An Uncommon Case of Recurring Pulmonary, Lymphatic, and Skeletal Tuberculosis Accompanied by Myositis: Is It Associated with Particular Resistance?
Abstract
Tuberculosis (TB) remains one of the primary causes of illness and death worldwide. Indonesia ranks second globally in TB incidence. Recurrent or relapsed TB, especially with multifocal involvement, presents significant diagnostic and therapeutic challenges, often complicated by incomplete treatment and limited molecular diagnostic capacity in developing countries. We present the case of a 26-year-old woman with a history of pulmonary, lymphatic, and skeletal tuberculosis who developed recurrence shortly after completing a 12-month anti-tuberculosis regimen (August 2024-July 2025) that excluded pyrazinamide due to gastrointestinal intolerance. She presented again in September 2025 with right-sided chest pain, productive cough, and cervical lymphadenopathy. Chest radiography revealed bilateral infiltrates, and abdominal ultrasonography suggested tuberculous myositis. The pulmonary findings, positive GeneXpert MTB/RIF Ultra result, and cervical lymph node biopsy confirming caseating granulomatous lymphadenitis were identified during the initial emergency department admission, while pus culture from the osteomyelitis lesion grew Staphylococcus aureus. The abdominal findings, including a left iliopsoas abscess with involvement of the iliacus muscle suggestive of tuberculous myositis, were detected later during outpatient follow-up evaluation, after the patient continued to experience persistent abdominal pain. The patient subsequently underwent a second course of treatment with…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.